Figure 3 from Targeting c-MET for Endoscopic Detection of Dysplastic Lesions within Barrett’s Esophagus Using EMI-137 Fluorescence Imaging
Huang Y-J., Rieder J., Tan KV., Tenditnaya A., Vojnovic B., Gorpas D., Quante M., Vallis KA.
<p><i>In vivo</i> and <i>ex vivo</i> fluorescence imaging of EMI-137 in the dual xenograft model: <b>A,</b><i>In vivo</i> fluorescence imaging 3 hours p.i. of EMI-137 showed a strong signal in the OE33 xenograft (right flank, white circle) but not in the FLO-1 xenograft (left flank, gray circle). <b>B,</b> Uptake of EMI-137 in OE33 tumors is effectively but not completely suppressed by coinjecting a 10-fold molar excess of unlabeled EMI-137 as a competitive blocking agent. <b>C,</b> Representative <i>ex vivo</i> tumor and organ panel of the dual xenograft model 3 hours p.i. of EMI-137 showing high uptake in OE33 tumor and kidney. <b>D,</b><i>Ex vivo</i> tumor and organ panel taken from mice that received EMI-137 plus unlabeled EMI-137 coinjection as a blocking agent. <b>E,</b> Average radiant efficiency in tumors and organs 3 hours p.i. of EMI-137. <b>F,</b> Average radiant efficiency in tumors and organs 3 hours p.i. of EMI-137 plus a 10-fold molar excess of unlabeled EMI-137 showed more than 50% reduction of fluorescence in OE33 xenograft compared with <b>E</b>. <i>n</i> = 3 mice per group. ****, <i>P</i> < 0.0001. Avg, average; Max, maximum; Min, minimum; ns, not significant.</p>